Pfizer Inc (NYSE:PFE) Move as Institutional Investors’ Sentiment Up

Pfizer Inc. (NYSE:PFE) Logo

Sentiment for Pfizer Inc (NYSE:PFE)

Pfizer Inc (NYSE:PFE) institutional sentiment increased to 0.84 in 2019 Q2. Its up 0.08, from 0.76 in 2019Q1. The ratio has increased, as 642 investment managers opened new or increased equity positions, while 765 decreased and sold stakes in Pfizer Inc. The investment managers in our partner’s database now have: 3.85 billion shares, down from 3.88 billion shares in 2019Q1. Also, the number of investment managers holding Pfizer Inc in their top 10 equity positions decreased from 141 to 135 for a decrease of 6. Sold All: 51 Reduced: 714 Increased: 520 New Position: 122.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $203.68 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 17.02 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

The stock decreased 1.22% or $0.45 during the last trading session, reaching $36.83. About 15.20 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 0.65% since September 13, 2018 and is uptrending. It has outperformed by 0.65% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on October, 29. They expect $0.62 earnings per share, down 20.51 % or $0.16 from last year’s $0.78 per share. PFE’s profit will be $3.43 billion for 14.85 P/E if the $0.62 EPS becomes a reality. After $0.80 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -22.50 % negative EPS growth.

Northeast Financial Consultants Inc holds 10.65% of its portfolio in Pfizer Inc. for 2.40 million shares. Cincinnati Casualty Co owns 236,400 shares or 7.87% of their US portfolio. Moreover, Excalibur Management Corp has 6.01% invested in the company for 150,626 shares. The Delaware-based Cypress Capital Management Llc has invested 4.86% in the stock. Bruce & Co. Inc., a Illinois-based fund reported 508,832 shares.

Since January 1, 0001, it had 1 buy, and 0 selling transactions for $104,160 activity.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Ratings analysis reveals 0 of Pfizer’s analysts are positive. Out of 2 Wall Street analysts rating Pfizer, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $3600 while the high is $48. The stock’s average target of $40.67 is 10.43% above today’s ($36.83) share price. PFE was included in 9 notes of analysts from April 1, 2019. Bank of America maintained Pfizer Inc. (NYSE:PFE) on Monday, April 1 with “Buy” rating. DZ Bank upgraded it to “Hold” rating and $3600 target in Wednesday, August 28 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, August 27.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Pfizer Looks To Expand Market Opportunity For Its Blockbuster Drug Xtandi – Seeking Alpha” on September 13, 2019, also with their article: “Leaner Pfizer Positioned to Boost R&D Output – Yahoo Finance” published on September 11, 2019, published: “Why Jim Cramer’s Negative Take on Pfizer Is Flat-Out Wrong – The Motley Fool” on August 27, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: and their article: “Pfizer (PFE) Announces Prelim. Results from Proof-of-Concept Phase 2 Study of 20-Valent Pneumococcal Conjugate Vaccine Candidate –” published on September 09, 2019 as well as‘s news article titled: “The reasons – and researcher – behind Pfizer’s decision to expand in Sanford – Triangle Business Journal” with publication date: August 21, 2019.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.